Genentech, a member of the Roche Group, is set to present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 in London on July 12-15. These findings showcase the companies’ ongoing commitment to developing next-generation treatments and diagnostic tests aimed at slowing or stopping the progression of Alzheimer’s disease.

Biogen will present new findings at the Alzheimer’s Association International Conference (AAIC) 2026, set for July 12–15 in London. This includes data from the Phase 2 CELIA study of diranersen, an investigational tau-targeting ASO, as well as additional analyses of LEQEMBI (lecanemab).